Winona Ideal Patient Profile: Who It's Best For (and Who Should Look Elsewhere)

What Winona Actually Is (and Is Not)

Winona is a menopause-focused telehealth company founded in 2019 and operating in all 50 US states. Its model is straightforward: a woman completes a detailed symptom and medical-history questionnaire, a licensed clinician reviews it, and a prescription for FDA-approved hormones ships directly from a compounding or commercial pharmacy. No insurance is accepted, which keeps overhead low but shifts the full cost to the patient.

The platform does not prescribe peptides, GLP-1 agonists, or testosterone for women as its core offering. Its clinical lane is narrow on purpose: perimenopause and menopause symptom management through estrogen-based hormone replacement therapy (HRT).

What "Bioidentical" Means in This Context

Winona markets its hormones as "bioidentical," a term that causes confusion. In clinical practice, bioidentical means the hormone molecule is structurally identical to the one the human body produces. Estradiol (17-beta-estradiol) and micronized progesterone meet that definition and are available as FDA-approved products, including Estrace, Prometrium, and the Vivelle-Dot patch. FDA-approved bioidentical products carry a full safety and efficacy dossier; custom-compounded "bioidentical" products do not. Winona prescribes both FDA-approved commercial products and, in some cases, compounded formulations. Patients should ask explicitly which category their prescription falls into.

Regulatory Standing

Winona operates under standard state telehealth laws and prescribes within the scope of those laws. The FDA has not approved or certified any telehealth platform, so "FDA-approved" refers to the drugs, not the company. That distinction matters when evaluating marketing language.

The Clinical Evidence for Menopause HRT That Winona Cites

Winona's prescribing approach references the 2022 Menopause Society (formerly NAMS) position statement, which concluded that hormone therapy is the most effective treatment for vasomotor symptoms and is appropriate for healthy women within 10 years of menopause onset or under age 60. The 2022 NAMS Hormone Therapy Position Statement states: "For women aged younger than 60 years or within 10 years of menopause onset and without contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms."

That guidance reversed a decade of overcautious prescribing that followed the Women's Health Initiative (WHI) trial, whose 2002 results were widely misread as condemning all HRT. A 2017 re-analysis of WHI data published in JAMA (N=27,347 randomized participants) found that conjugated equine estrogen plus medroxyprogesterone acetate increased breast cancer risk only after 5 or more years of use, and that estrogen-alone therapy in women who had undergone hysterectomy was associated with a reduced risk of breast cancer at 18-year follow-up. WHI re-analysis, Chlebowski et al., JAMA 2017.

The Vasomotor Symptom Burden

Approximately 75% of menopausal women experience hot flashes, and roughly 25 to 30% describe them as severe enough to disrupt sleep and daily function. Thurston et al., published in Obstet Gynecol 2011. Oral estradiol reduces hot flash frequency by approximately 75% compared to placebo in randomized trials. That number comes from the REPLENISH trial (N=1,835), which tested oral 17-beta-estradiol/progesterone combination capsules and found a statistically significant reduction in mean daily moderate-to-severe hot flashes at 12 weeks versus placebo (P<0.001). REPLENISH trial, Kagan et al., Menopause 2019.

Bone and Cardiovascular Context

Beyond symptom relief, estrogen therapy preserves bone mineral density. The Women's Health Initiative bone substudy showed that combined HRT reduced hip fracture incidence by 34% over 5.6 years Anderson et al., JAMA 2004. Cardiovascular effects are timing-dependent: starting HRT within 10 years of menopause may reduce coronary artery disease risk, while starting after age 60 or more than 10 years after menopause may increase it. This "timing hypothesis" now anchors the NAMS 2022 guidance and directly shapes which patients are good candidates for a platform like Winona.

The Winona Ideal Patient Profile

Not every menopausal woman is the right fit for an async-first telehealth HRT service. The following profile is based on published eligibility criteria from NAMS 2022, FDA labeling for estradiol products, and the platform's own publicly stated intake process.

Who Is the Best Candidate

A woman is likely a good fit for Winona if she meets all of the following conditions:

• She is between the ages of 40 and 60 and within 10 years of her last menstrual period.
• She has bothersome vasomotor symptoms: hot flashes, night sweats, sleep disruption, or mood instability related to estrogen decline.
• She has no personal history of hormone-receptor-positive (ER/PR-positive) breast cancer, active deep vein thrombosis, pulmonary embolism, or active liver disease.
• She has had a routine gynecologic exam within the past 1 to 3 years and knows her mammogram status.
• She prefers the convenience of mail-order prescriptions over monthly in-office visits.
• She can afford $99, $199 per month out-of-pocket and understands no insurance reimbursement is available.
• She has a primary care provider or gynecologist she can see for annual labs (Winona does not replace routine preventive care).

Who Should Not Use Winona

Certain clinical histories require in-person specialist evaluation that a questionnaire-based platform cannot safely provide:

• Personal history of breast cancer (any subtype), endometrial cancer, or ovarian cancer.
• Active or recent (within 12 months) thromboembolic event (DVT or PE).
• Undiagnosed abnormal uterine bleeding. This requires endometrial biopsy or transvaginal ultrasound before any progestogen decision.
• Migraine with aura, especially if poorly controlled. Estrogen can increase stroke risk in this population per a 2017 systematic review in the BMJ Sheikh et al., BMJ 2017.
• Women more than 10 years postmenopausal starting HRT for the first time, unless an in-person cardiovascular risk assessment has been completed.
• Women who need testosterone therapy for hypoactive sexual desire disorder (HSDD). Winona does not currently offer this as a primary service, and NAMS recommends testosterone only under specialist guidance for HSDD Davis et al., Menopause 2019.

The Perimenopause Gray Zone

Perimenopause is the period of irregular cycles and fluctuating estrogen that precedes the final menstrual period, often lasting 4 to 10 years. Diagnosing it reliably requires clinical context, not just an FSH level, because FSH fluctuates widely in this window. A 2021 review in The Lancet noted that FSH above 40 IU/L on two measurements taken 4 to 6 weeks apart supports but does not confirm menopause. Hamoda et al., Lancet 2021.

Winona's intake questionnaire asks symptom-based questions rather than relying solely on lab values, which aligns with NAMS guidance that menopause is a clinical diagnosis in women over 45. Younger women (ages 40 to 45) with symptoms should be asked whether premature ovarian insufficiency (POI) has been ruled out, because POI requires a different clinical approach and carries higher long-term bone and cardiovascular risk.

What Winona Prescribes: Formulations and Doses

Winona prescribes within the standard estradiol dose range recognized in US guidelines. The following are the most commonly issued formulations.

Oral Estradiol

Oral 17-beta-estradiol is the most commonly prescribed systemic estrogen in the US. Standard starting doses range from 0.5 mg to 1 mg daily, titrated based on symptom response. Oral estradiol undergoes first-pass hepatic metabolism, which raises SHBG and triglycerides more than transdermal delivery. Women with baseline hypertriglyceridemia or a history of gallstone disease may tolerate a transdermal route better. Stuenkel et al., J Clin Endocrinol Metab 2015.

Transdermal Estradiol

Patches (0.025 to 0.1 mg/day) and gels bypass the liver entirely. The ESTHER study (N=881) found that transdermal estradiol, unlike oral estradiol, did not increase VTE risk (odds ratio 0.9, 95% CI 0.4 to 2.1), while oral estrogen was associated with a fourfold increase in VTE risk in that cohort. Canonico et al., Circulation 2007. Women with personal or family history of VTE should ask specifically about the patch or gel.

Progesterone

Women with an intact uterus must take a progestogen alongside estrogen to prevent endometrial hyperplasia. Winona prescribes micronized progesterone (Prometrium 100 to 200 mg/day), which has a more favorable cardiovascular and mood profile than synthetic progestins. The KEEPS trial (N=727) found no significant difference in intima-media thickness between oral micronized progesterone and transdermal progesterone groups, but both outperformed medroxyprogesterone acetate on patient-reported sleep outcomes. Harman et al., Ann Intern Med 2014.

Vaginal Estrogen

Low-dose vaginal estradiol (Vagifem 10 mcg, or estradiol cream 0.01%) treats genitourinary syndrome of menopause (GSM): vaginal dryness, dyspareunia, and recurrent UTIs. Systemic absorption is minimal at low doses. The NAMS 2020 GSM position statement says vaginal estrogen is safe even for most breast cancer survivors taking aromatase inhibitors, with oncologist sign-off. NAMS 2020 GSM statement.

Is Winona Legit? Evaluating the Platform Critically

"Is Winona legit" is one of the top search queries for this brand, and the question deserves a direct answer with criteria, not marketing language.

Licensing and Clinician Credentials

Winona employs licensed physicians and nurse practitioners who hold active state licenses. The platform is not a nurse-only model. Prescriptions are generated by licensed clinicians, not AI algorithms. That places it on firmer ground than some competitors that have faced FDA warning letters for AI-generated prescribing.

Compounding Transparency

Some Winona formulations come from 503A compounding pharmacies. These pharmacies are regulated by state boards of pharmacy and must comply with USP Chapter 795 standards, but they do not go through FDA's new drug approval process. Patients should ask at intake whether their prescription is an FDA-approved commercial product or a compounded formulation, and request the pharmacy's name and accreditation.

No Insurance, No Lab Ordering

Winona does not accept insurance and does not order or interpret labs as part of its service. Women need to get baseline estradiol, FSH, and thyroid labs through their primary care provider before or during treatment. This is a meaningful limitation. Symptom-only prescribing without baseline labs can miss hypothyroidism, which shares many symptoms with perimenopause and affects approximately 5% of US women. Garber et al., Thyroid 2012.

Patient Satisfaction Data

Independent review aggregators (not the Winona website) report an average rating of approximately 4.2 to 4.5 out of 5 across several hundred reviews, with high marks for clinician responsiveness and prescription speed, and lower marks for customer service when billing issues arise. These ratings are observational and subject to selection bias; they are not a substitute for controlled outcome data.

Winona vs. Alternatives: A Direct Comparison

Several telehealth HRT platforms compete in this space. The comparison below focuses on clinical differentiators, not marketing claims.

Winona vs. Midi Health

Midi Health accepts insurance in many states and employs a multi-specialty team that includes menopause-certified physicians. Its intake process is synchronous (live video required), which adds friction but allows for more nuanced clinical assessment. Women with complex medical histories or who want insurance coverage should favor Midi.

Winona vs. Alloy Women's Health

Alloy offers a lower entry price point (starting around $49/month for vaginal estrogen) and uses FDA-approved commercial products only. No compounded formulations are offered. Women who want the security of a strictly commercial-product formulary may prefer Alloy.

Winona vs. In-Person Gynecology

In-person gynecology remains the gold standard for women with complex histories, abnormal bleeding, or who need procedures such as endometrial biopsy, IUD placement, or breast imaging review. A 2023 survey in Menopause journal found that fewer than 30% of OB-GYN residents felt adequately trained in menopause management, suggesting that a knowledgeable telehealth clinician may sometimes provide better guideline-concordant care than a generalist in-person provider. Kaunitz et al., Menopause 2023.

How Much Does Winona Cost?

Winona's pricing is cash-pay and varies by formulation. As of mid-2025, publicly listed prices are approximately:

• Oral estradiol plus progesterone: $99, $149/month
• Transdermal estradiol patch: $119, $169/month
• Vaginal estradiol cream or suppository: $79, $119/month
• Testosterone cream (if offered): $129, $199/month

Prices include the clinician consultation fee and prescription. Pharmacy shipping is typically included. No HSA/FSA reimbursement restrictions apply to prescription medications, so patients with these accounts can use pre-tax dollars to pay, reducing effective out-of-pocket cost by 20 to 35% depending on their marginal tax rate.

Winona Reviews: What Real Patients Report

Aggregated patient feedback across independent review platforms points to several consistent themes. Positive reports center on the speed of receiving a prescription (often within 24 hours), the quality of clinician communication through the patient portal, and the relief of symptoms after 4 to 8 weeks of therapy. Negative reports most frequently cite difficulty reaching customer support for billing corrections and a lack of proactive follow-up labs.

One pattern worth noting: women who enter with clear, uncomplicated symptom profiles (classic hot flashes, night sweats, no significant comorbidities) report higher satisfaction than women who present with mixed or atypical symptoms. This tracks with the platform's clinical design, which was built for the straightforward case.

A Note on Duration of Therapy

NAMS 2022 states there is no mandatory time limit for HRT in healthy women who continue to benefit and who have no contraindications. The old "5-year rule" derived from a misreading of WHI data. The guideline recommends annual reassessment of the benefit-risk balance, not automatic discontinuation. Women using Winona should plan for that annual conversation with their clinician, whether through the platform or their in-person provider.

The WISDOM trial extension data (N=4,894, follow-up to 11 years) found no statistically significant increase in breast cancer mortality in women who used combined HRT for up to 7 years when started within 10 years of menopause. Currie et al., BMJ 2021.